Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
9.01 x 1 9.72 x 1
Post-market by (Cboe BZX)
9.33 +1.16 (+14.20%) 04/21/25 [NASDAQ]
9.01 x 1 9.72 x 1
Post-market 9.72 +0.39 (+4.15%) 16:52 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.01
Day High
9.79
Open 8.17
Previous Close 8.17 8.17
Volume 4,505,900 4,505,900
Avg Vol 2,719,020 2,719,020
Stochastic %K 49.34% 49.34%
Weighted Alpha -56.68 -56.68
5-Day Change +2.29 (+32.53%) +2.29 (+32.53%)
52-Week Range 6.36 - 47.45 6.36 - 47.45
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 928,390
  • Shares Outstanding, K 113,634
  • Annual Sales, $ 0 K
  • Annual Income, $ -317,420 K
  • EBIT $ -344 M
  • EBITDA $ -346 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.27

Options Overview Details

View History
  • Implied Volatility 138.45% ( -13.94%)
  • Historical Volatility 104.15%
  • IV Percentile 90%
  • IV Rank 53.67%
  • IV High 223.59% on 04/10/25
  • IV Low 39.80% on 06/18/24
  • Put/Call Vol Ratio 0.77
  • Today's Volume 117
  • Volume Avg (30-Day) 195
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 973
  • Open Int (30-Day) 3,814

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.88
  • Number of Estimates 8
  • High Estimate -0.82
  • Low Estimate -0.92
  • Prior Year -0.81
  • Growth Rate Est. (year over year) -8.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.36 +46.70%
on 04/09/25
Period Open: 12.08
12.43 -24.92%
on 03/24/25
-2.75 (-22.76%)
since 03/21/25
3-Month
6.36 +46.70%
on 04/09/25
Period Open: 14.55
17.17 -45.68%
on 02/06/25
-5.22 (-35.88%)
since 01/21/25
52-Week
6.36 +46.70%
on 04/09/25
Period Open: 23.86
47.45 -80.34%
on 08/20/24
-14.53 (-60.90%)
since 04/19/24

Most Recent Stories

More News
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

DYN : 9.33 (+14.20%)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DYN : 9.33 (+14.20%)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

DYN : 9.33 (+14.20%)
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

DYN : 9.33 (+14.20%)
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

DYN : 9.33 (+14.20%)
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

DYN : 9.33 (+14.20%)
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

DYN : 9.33 (+14.20%)
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

DYN : 9.33 (+14.20%)
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

DYN : 9.33 (+14.20%)
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...

CORT : 62.90 (+1.06%)
DYN : 9.33 (+14.20%)
CRDL : 0.9700 (-3.96%)
AMRX : 7.13 (-3.13%)
NKTR : 0.6259 (-1.65%)
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...

CORT : 62.90 (+1.06%)
DYN : 9.33 (+14.20%)
CRDL : 0.9700 (-3.96%)
AMRX : 7.13 (-3.13%)
NKTR : 0.6259 (-1.65%)
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

DYN : 9.33 (+14.20%)
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for...

DYN : 9.33 (+14.20%)
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

DYN : 9.33 (+14.20%)
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

DYN : 9.33 (+14.20%)
Insider Sale: Chief Scientific Officer of $DYN (DYN) Sells 2,334 Shares

Oxana Beskrovnaya, the Chief Scientific Officer of $DYN ($DYN), sold 2,334 shares of the company on 12-11-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

DYN : 9.33 (+14.20%)
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

DYN : 9.33 (+14.20%)
Dyne Therapeutics to Present at Upcoming Investor Conferences

DYN : 9.33 (+14.20%)
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

DYN : 9.33 (+14.20%)
2 Breakout Biotech Stocks With CEO Insider Buying

These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?

RLMD : 0.3230 (+11.46%)
DYN : 9.33 (+14.20%)

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 11.86
2nd Resistance Point 10.82
1st Resistance Point 10.08
Last Price 9.33
1st Support Level 8.30
2nd Support Level 7.26
3rd Support Level 6.52

See More

52-Week High 47.45
Fibonacci 61.8% 31.75
Fibonacci 50% 26.91
Fibonacci 38.2% 22.06
Last Price 9.33
52-Week Low 6.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro